Beam Therapeutics
Develops base-edited medicines for sickle cell disease and inherited metabolic disorders.
$29.32
After-hours close+0.03 (+0.10%)
At close$29.29(−3.90%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 110.57%Insiders 1.58%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 102.88M · Float 88.30M · 85.8% free float
Institutions13F, as of Jun 30, 2026
285 holders · 113.76M shares · 61 new positions · 155 increased · 76 reduced · 36 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 12.61M | 12.26% | +156.8K | Aug 13, 2026 |
| Farallon Capital Management LLC | 10.24M | 9.95% | +101.7K | Aug 14, 2026 |
| Ark Investment Management LLC | 10.23M | 9.95% | −1.90M | Aug 14, 2026 |
| BlackRock, Inc. | 9.00M | 8.75% | +510.0K | Aug 7, 2026 |
| State Street Corp | 5.83M | 5.66% | +127.9K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 4.92M | 4.78% | +350.5K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.60M | 4.47% | +222.1K | Aug 13, 2026 |
| Arch Venture Management, LLC | 4.54M | 4.41% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 12.60% | 12.75M | 13G | Feb 5, 2026 ↗ |
| ARK Investment Management LLC | 12.29% | 12.47M | 13G | Feb 3, 2026 ↗ |
| BlackRock, Inc. | 7.50% | 7.50M | 13G | Apr 17, 2025 ↗ |
| State Street Corporation | 5.20% | 5.23M | 13G | Feb 9, 2026 ↗ |
| Vanguard Capital Management | 5.02% | 5.12M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| John M. Evans | director, officer: CEO | 1.05M | 1.02% | Jul 1, 2026 |
| FMR LLC | 10 percent owner, other: See Remark 1 | 854.6K | 0.83% | Jun 29, 2026 |
| Giuseppe Ciaramella | officer: President | 224.9K | 0.22% | Jun 22, 2026 |
| Christine Bellon | officer: Chief Legal Officer | 109.7K | 0.11% | Apr 6, 2026 |
| Sravan Kumar Emany | officer: Chief Financial Officer | 105.5K | 0.10% | Apr 2, 2026 |
| Amy Simon | officer: Chief Medical Officer | 85.7K | 0.08% | Jul 29, 2026 |
| Bethany J. Cavanagh | officer: SVP, Finance and Treasurer | 51.2K | 0.05% | Apr 6, 2026 |
3 ten-percent owners hold 14.38M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 8 people have not refiled in the last 18 months (1.31M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 27, 2026 | Amy Simonofficer: Chief Medical Officer | Sale | 16,667 | $25.74 | 85,696 |
| Jun 30, 2026 | Amy Simonofficer: Chief Medical Officer | Sale | 373 | $34.73 | 102,363 |
| Jun 29, 2026 | John M. Evansdirector, officer: CEO | Sale · 2 lots | 25,000 | $35.49 | 1,047,205 |
| Jun 30, 2026 | John M. Evansdirector, officer: CEO | Sale · 2 lots | 25,000 | $34.31 | 1,047,205 |
| Jun 26, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sale | 251,488 | $35.26 | 854,583 |
| Jun 25, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sale | 33,372 | $35.12 | 1,106,071 |
| Apr 1, 2026 | Giuseppe Ciaramellaofficer: President | Sale | 11,810 | $24.58 | 218,406 |
| Apr 1, 2026 | Christine Bellonofficer: Chief Legal Officer | Sale | 5,956 | $24.58 | 109,711 |
| Apr 1, 2026 | Bethany J. Cavanaghofficer: SVP, Finance and Treasurer | Sale | 3,242 | $24.58 | 51,171 |
| Apr 1, 2026 | Amy Simonofficer: Chief Medical Officer | Sale | 6,700 | $24.58 | 102,735 |
CongressHouse and Senate disclosures
Not reported.